Exelixis (EXEL) to Release Earnings on Tuesday

Exelixis (NASDAQ:EXEL) is expected to release its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect Exelixis to post earnings of $0.68 per share and revenue of $590.0350 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 5:00 PM ET.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $38.67 on Monday. The business’s 50 day moving average price is $38.81 and its 200-day moving average price is $40.28. The firm has a market capitalization of $10.41 billion, a PE ratio of 18.59, a P/E/G ratio of 0.79 and a beta of 0.38. Exelixis has a 1 year low of $31.90 and a 1 year high of $49.62.

Institutional Investors Weigh In On Exelixis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EXEL. Geneos Wealth Management Inc. raised its holdings in shares of Exelixis by 134.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 944 shares during the period. Evergreen Capital Management LLC acquired a new position in Exelixis during the 2nd quarter worth $226,000. Benjamin Edwards Inc. acquired a new position in Exelixis during the 2nd quarter worth $255,000. Baird Financial Group Inc. acquired a new position in Exelixis during the 2nd quarter worth $259,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in Exelixis by 163.0% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 7,297 shares of the biotechnology company’s stock worth $322,000 after purchasing an additional 4,522 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. The Goldman Sachs Group assumed coverage on Exelixis in a research report on Wednesday, September 17th. They set a “buy” rating and a $47.00 price objective on the stock. Truist Financial reduced their price objective on Exelixis from $56.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, July 29th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $45.00 price objective on shares of Exelixis in a research report on Tuesday, October 21st. Citigroup reiterated a “market outperform” rating on shares of Exelixis in a research report on Tuesday, October 21st. Finally, Wells Fargo & Company reduced their price objective on Exelixis from $36.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Tuesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $44.53.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.